Psychosomatic Medicine

Skip Navigation LinksHome > June 2014 - Volume 76 - Issue 5 > Efficacy, Tolerability, and Safety of Hypnosis in Adult Irri...
Psychosomatic Medicine:
doi: 10.1097/PSY.0000000000000039
Systematic Review/Meta-Analysis

Efficacy, Tolerability, and Safety of Hypnosis in Adult Irritable Bowel Syndrome: Systematic Review and Meta-Analysis

Schaefert, Rainer MD; Klose, Petra PhD; Moser, Gabriele MD; Häuser, Winfried MD

Supplemental Author Material
Collapse Box


Objective: To assess the efficacy, tolerability, and safety of hypnosis in adult irritable bowel syndrome by a meta-analysis of randomized controlled trials.

Methods: Studies were identified by a literature search of the databases Allied and Complementary Medicine Database, Central Register of Controlled Trials, Cumulative Index to Nursing and Allied Health Literature, PubMed, PsycINFO, and Scopus (from inception to June 30, 2013). Primary outcomes were adequate symptom relief, global gastrointestinal score, and safety. Summary relative risks (RRs) with number needed to treat (NNT) and standardized mean differences (SMDs) with 95% confidence intervals (95% CIs) were calculated using random-effects models.

Results: Eight randomized controlled trials with a total of 464 patients and a median of 8.5 (7–12) hypnosis sessions over a median of 12 (5–12) weeks were included into the analysis. At the end of therapy, hypnosis was superior to control conditions in producing adequate symptom relief (RR, 1.69 [95% CI = 1.14–2.51]; NNT, 5 [3–10]) and in reducing global gastrointestinal score (SMD, 0.32 [95% CI = −0.56 to −0.08]). At long-term follow-up, hypnosis was superior to controls in adequate symptom relief (RR, 2.17 [95% CI = 1.22–3.87]; NNT, 3 [2–10]), but not in reducing global gastrointestinal score (SMD, −0.57 [−1.40 to 0.26]). One (0.4%) of 238 patients in the hypnosis group dropped out due to an adverse event (panic attack).

Conclusion: This meta-analysis demonstrated that hypnosis was safe and provided long-term adequate symptom relief in 54% of patients with irritable bowel syndrome refractory to conventional therapy.

Copyright © 2014 by American Psychosomatic Society

You currently do not have access to this article.

You may need to:

Note: If your society membership provides for full-access to this article, you may need to login on your society’s web site first.


Article Tools


Article Level Metrics

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.